Prostate cancer is one of the most common cancers in men. Blood tests are currently determining if there is primary prostate cancer. However, the accuracy of the diagnosis is only 30%, so many patients have to undergo invasive biopsy after a blood test and suffer from side effects such as bleeding and suffering.
Last December, Korea Advanced Institute of Science and Technology (KIST) announced that Dr. Lee Kwan-hee’s team at the Center for Biological Materials Research has developed a technology to diagnose prostate cancer in urine with nearly 100% accuracy in just 20 minutes. The research team introduced a smart artificial intelligence analysis method in biosensors based on ultra-high sensitivity electric signals. The study was published in ACS Nano (IF 14.588).
Diagnostic tests using urine are convenient for patients and do not require an invasive biopsy, so cancer can be diagnosed without side effects or patient pain. However, urine-based biosensors have been used to classify dangerous groups rather than precision diagnosis because the concentration of canker metastasis is low in the urine.
Dr. Lee Kwan-hee’s team has developed a technology to diagnose diseases in urine using the ultra-high sensitivity biosensor based on electrical signals. With regard to cancer diagnosis, a single scanner metastasis limited the accuracy of the diagnosis to over 90%. To solve this issue, the researchers simultaneously utilized several different types of cancer metastasis rather than one.